Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Medical ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The normal menopause transition.Maturitas. 1992; 14: 103-115
- Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging.J Clin Endocrinol Metab. 2012; 97: 1159-1168
- Characterizing the trajectories of vasomotor symptoms across the menopausal transition.Menopause. 2016; 23: 1067-1074
- Genitourinary syndrome of menopause. Prevalence and quality of life in Spanish postmenopausal women. The GENISSE study.Climacteric. 2018; 21: 167-173
- A longitudinal analysis of the association between menopause and depression. Results from the Massachusetts Women's Health Study.Ann Epidemiol. 1994; 4: 214-220
- Sleep difficulty in women at midlife: a community survey of sleep and the menopausal transition.Menopause. 2003; 10: 19-28
- Midlife women's attributions about perceived memory changes: observations from the Seattle Midlife Women's Health Study.J Womens Health Gend Based Med. 2001; 10: 351-362
- Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from the Study of Women's Health Across the Nation (SWAN).J Bone Miner Res. 2012; 27: 111-118
- Management of menopause-related symptoms.Evid Rep Technol Assess (Summ). 2005; 120 (Available at:): 1-6
- Hormone therapy in postmenopausal women and risk of endometrial hyperplasia.Cochrane Database Syst Rev. 2012; 8: CD000402
- Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.JAMA. 2002; 288: 321-333
- Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.JAMA. 2007; 297: 1465-1477
- The 2017 hormone therapy position statement of The North American Menopause Society.Menopause. 2017; 24: 728-753
- Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials.JAMA. 2017; 318: 927-938
- Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials.JAMA. 2020; 324: 369-380
- Hormone therapy for preventing cardiovascular disease in post-menopausal women.Cochrane Database Syst Rev. 2015; : CD002229https://doi.org/10.1002/14651858.CD002229.pub4
- Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases.BMJ. 2019; 364: k4810
- Unopposed estrogen therapy and the risk of invasive breast cancer.Arch Intern Med. 2006; 166: 1027-1032
- Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.JAMA. 2013; 310: 1353-1368
- Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence.Lancet. 2019; 394: 1159-1168
- Menopausal Hormone Therapy.JAMA. 2019; 321: 2458-2459
- Use of oral contraceptives by women with epilepsy.JAMA. 1986; 256 (Available at:): 238-240
- The National Academies of Science, Engineering, and Medicine (NASEM) Report on Compounded Bioidentical Hormone Therapy.Menopause. 2020; 27: 1199-1201
- Discontinuing postmenopausal hormone therapy: an observational study of tapering versus quitting cold turkey: is there a difference in recurrence of menopausal symptoms?.Menopause. 2009; 16: 494-499
- The North American Menopause Society Statement on Continuing Use of Systemic Hormone Therapy After Age 65.Menopause. 2015; 22: 693
- Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial.JAMA. 2003; 289: 2827-2834
- Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9.J Clin Oncol. 2010; 28: 3278-3283
- Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial.JAMA. 2011; 305: 267-274
- Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial.Lancet. 2000; 356: 2059-2063
- Desvenlafaxine compared with placebo for treatment of menopausal vasomotor symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind, placebo-controlled efficacy trial.Menopause. 2013; 20: 28-37
- Non-hormonal interventions for hot flushes in women with a history of breast cancer.Cochrane Database Syst Rev. 2010; 9: CD004923
- SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials.J Gen Intern Med. 2014; 29: 204-213
- Use of gabapentin in patients experiencing hot flashes.Pharmacotherapy. 2009; 29: 74-81
- Use of gabapentin for the management of natural or surgical menopausal hot flashes.Ann Pharmacother. 2011; 45: 388-394
- Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial.Obstet Gynecol. 2006; 108: 41-48
- Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study.Ann Intern Med. 2000; 132: 788-793
- Use of alternative therapies for menopause symptoms: results of a population-based survey.Obstet Gynecol. 2002; 100: 18-25
- A randomised controlled trial of a cognitive behavioural intervention for women who have menopausal symptoms following breast cancer treatment (MENOS 1): trial protocol.BMC Cancer. 2011; 11: 44
- Effectiveness of group and self-help cognitive behavior therapy in reducing problematic menopausal hot flushes and night sweats (MENOS 2): a randomized controlled trial.Menopause. 2012; 19: 749-759
- Clinical hypnosis in the treatment of postmenopausal hot flashes: a randomized controlled trial.Menopause. 2013; 20: 291-298
- Mindfulness training for coping with hot flashes: results of a randomized trial.Menopause. 2011; 18: 611-620
- Effects of stellate ganglion block on vasomotor symptoms: findings from a randomized controlled clinical trial in postmenopausal women.Menopause. 2014; 21: 807-814
- An intensive behavioral weight loss intervention and hot flushes in women.Arch Intern Med. 2010; 170: 1161-1167
- Use of Plant-Based Therapies and Menopausal Symptoms: A Systematic Review and Meta-analysis.JAMA. 2016; 315: 2554-2563
Article info
Publication history
Published online: December 27, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
